TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in pain as measured by WOMAC pain subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in function as measured by WOMAC function subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject global assessment of response to therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: level of sensory block duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete molecular response (CMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating disorder diagnosis during follow-up in registers
Endpoint domain: Mortality/survival
Primary endpoint: Maternal recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence and Severity of Complications and Morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Blood drug concentration of liposomal amphotericin B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: 36-item Short Form Health Survey (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Delta sCreat > 30%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: urine protein-to-creatinine (uPCR) < 1g/mmol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area under the receiver operating characteristic (AUROC) curves
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mesiodistal width of teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peri-implant keratinized mucosa width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peri-implant mucosa thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inpatient death rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with acute venous thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with pulmonary embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in GOSS scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Somatosensory Amplification Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prognosis prediction accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in metabolomics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in endocrine hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in the number of follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incidence of symptomatic COVID-19 cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Amsterdam Misophonia Scale (A-MIS-S)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pediatric Quality of Life PedQL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Increment of hepatic fat content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hepatic fat content values after fructose restriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of hepatic fatty acid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Menopause Symptoms Assessment Scale (MSAS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Menopause Specific Quality of Life Scale (MSQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Monthly Mortality Rate
Endpoint domain: Mortality/survival
Primary endpoint: Diagnostic accuracy of fracture detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in motion analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vo2 Max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accurate elevation of temperature measured by MRI thermometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and patient tolerance according to The adverse events (CTCAE v5.0)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in MDS-UPDRS Parts I-III score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spleen stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver and biliary outcomes
Primary endpoint: Establishment of B cell line
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: bleeding events at 12 months
Endpoint domain: Adverse events/effects
Primary endpoint: ischemic events at 12 months
Endpoint domain: Adverse events/effects
Primary endpoint: Ankle Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity Measure for Post-Acute Care (AM-PAC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tolerability of the CoolStat Device
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of the CoolStat Device
Endpoint domain: Adverse events/effects
Primary endpoint: post-laparoscopic shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minute ventilation-to-carbon dioxide output (VE/VCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen uptake/work (△VO2/△W) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with ≤ 5 letter loss in DVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival contour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-epithelialisation evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival distortion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Health Questionnaire for Adolescents (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of events with glucose levels ≥ 0.6 mmol/L lasting more than one hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of events with glucose levels ≥ 0.8 mmol/L lasting more than one hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of events with glucose levels ≥ 1.5 mmol/L lasting more than one hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of events with glucose levels ≥ 3.0 mmol/L lasting more than one hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dental Exam Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Treatment emergent adverse events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of participants who maintain ACR20 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gut Microbiota Composition Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Athletic Performance Improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction of dorsal ventilation at the end of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ocular itch score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: B-lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in haemophilia joint health score (HJHS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Progression Free Survival (PFS) Based on BIRC Assessment
Endpoint domain: Mortality/survival
Primary endpoint: Change in serum ACTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in serum GH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in plasma copeptin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Positive affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Negative affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 30m sprint test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ILLINOIS AGILITY TEST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurodevelopmental disorders detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: hearing disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mandatory or recommended vaccines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Disposition Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Economic impact of treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: KSS Test change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: KOOS Test change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SF-12 Test change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Successful outcome of pulpotomy versus RCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in CD71 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in CD35 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in CD47 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in CD55 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in CD59 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in RNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of grade 0 or 1 patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Planimetric plaque quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Successful CTO PCI procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Negativity rate of minimal residual disease (MRD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hip extensor strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Volume of upper limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or Absence of Significant PAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Thigh muscle strength test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cerebrovascular and cardiovascular physiology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of potential harmful side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change From Baseline in Daily Average Low Back Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Early and Mild Alzheimer's Cognitive Composite (EMACC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Timed Up and Go Test During Dual Tasking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geriatric Pain Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Older people's quality of life-brief (OPQOL-brief)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in frequency of seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in frequency of epileptiform discharges
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in synchronization of background ECoG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CBB Testing Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Age Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV Vaccine series initiation rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: HPV Vaccine series completion rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reach of the Study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reach of the Intervention Bundle
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Detection of epithelial ovarian cancer tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Measurable residual disease (MRD) status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper Extremity Muscle Strength Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants With Established Cardiovascular Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Chronic Kidney Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants With High Cardiovascular Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Light-dependent Change in Optical Coherence Tomography Images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression- Improvement (CGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Retention of the exercise program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to the exercise program
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Satisfaction of the program
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequency, duration, and severity of treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Dose-limiting toxicities (DLTs) of NC525
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the curve (AUC) from time zero to t (AUC(0-T))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) from time zero extrapolated to infinite time (AUC(INF))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast cancer event-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Time until return of bowel function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of pyridostigmine bromide associated side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Inflammation (pg/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lipid Panel (mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Exercise Induced Fat Oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reliability of the Arabic-translated NEURQOL Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the quality of sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: safety and tolerability of NLS-2
Endpoint domain: Adverse events/effects
Primary endpoint: Abdominal fat volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Automated PWD-MPI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Automated STIC Tricuspid, Mitral and Septal Annular Plane Systolic Excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bone structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adhesion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Implementation at home
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Online consultations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Satisfaction of tele-rehabilitation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Usability of virtual reality system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IIEF-EF sub scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical Success (intraoperative anastomosis patency)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Freedom from device-related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of type-specific HPV types
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of Return of Spontaneous Circulation (ROSC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SCAR-Q scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum Observed Concentration (Cmax) of PF-06480605
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for Cmax (Tmax) of PF-06480605
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time 0 to End of Dosing Interval (AUC14day) of PF-06480605
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-CHIKV SNA Titer (NT80) Seroresponse Rates at Day 22
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-CHIKV SNA Titer (NT80) Geometric Mean Titers (GMT) at Day 22
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in feeding practices
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in visuospatial cortex PiB distribution volume ratio (DVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under Plasma Concentration-Time Curve (AUC) Over the Dosing Interval (AUC0-τ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unanesthetized Schirmer test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anesthetized Schirmer test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in digitally assessed measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year progression free survival (PFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of subjects that achieved and/or maintained target ranges for oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects that achieved and/or maintained target ranges for ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of SGPT/ALT with Lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Correlation of SGPT/ALT with HFLC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parkinson's Disease-Cognitive Rating Scale (PD-CRS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Parkinson's Disease-Cognitive Functional Rating Scale (PD-CFRS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Client Satisfaction Questionnaire 8-item (CSQ-8)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 12-week post-operative serious device-related adverse event (SADE) rate
Endpoint domain: Adverse events/effects
Primary endpoint: Time to second generalized tonic-clonic (GTC) seizure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Processing Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of dietary intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plantar heel pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes